🇺🇸 FDA
Pipeline program

Rituximab

CR102604

Phase 3 small_molecule completed

Quick answer

Rituximab for Chronic Lymphocytic Leukemia is a Phase 3 program (small_molecule) at Janssen Cilag International NV with 1 ClinicalTrials.gov record(s).

Program details

Company
Janssen Cilag International NV
Indication
Chronic Lymphocytic Leukemia
Phase
Phase 3
Modality
small_molecule
Status
completed

Clinical trials